TY - JOUR T1 - Prior diagnoses and medications as risk factors for COVID-19 in a Los Angeles Health System JF - medRxiv DO - 10.1101/2020.07.03.20145581 SP - 2020.07.03.20145581 AU - Timothy S Chang AU - Yi Ding AU - Malika K Freund AU - Ruth Johnson AU - Tommer Schwarz AU - Julie M Yabu AU - Chad Hazlett AU - Jeffrey N Chiang AU - Ami Wulf AU - UCLA Precision Health Data Discovery Repository Working Group AU - Daniel H Geschwind AU - Manish J Butte AU - Bogdan Pasaniuc Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/07/04/2020.07.03.20145581.abstract N2 - With the continuing coronavirus disease 2019 (COVID-19) pandemic coupled with phased reopening, it is critical to identify risk factors associated with susceptibility and severity of disease in a diverse population to help shape government policies, guide clinical decision making, and prioritize future COVID-19 research. In this retrospective case-control study, we used de-identified electronic health records (EHR) from the University of California Los Angeles (UCLA) Health System between March 9th, 2020 and June 14th, 2020 to identify risk factors for COVID-19 susceptibility (severe acute respiratory distress syndrome coronavirus 2 (SARS-CoV-2) PCR test positive), inpatient admission, and severe outcomes (treatment in an intensive care unit or intubation). Of the 26,602 individuals tested by PCR for SARS-CoV-2, 992 were COVID-19 positive (3.7% of Tested), 220 were admitted in the hospital (22% of COVID-19 positive), and 77 had a severe outcome (35% of Inpatient). Consistent with previous studies, males and individuals older than 65 years old had increased risk of inpatient admission. Notably, individuals self-identifying as Hispanic or Latino constituted an increasing percentage of COVID-19 patients as disease severity escalated, comprising 24% of those testing positive, but 40% of those with a severe outcome, a disparity that remained after correcting for medical co-morbidities. Cardiovascular disease, hypertension, and renal disease were premorbid risk factors present before SARS-CoV-2 PCR testing associated with COVID-19 susceptibility. Less well-established risk factors for COVID-19 susceptibility included pre-existing dementia (odds ratio (OR) 5.2 [3.2-8.3], p=2.6 × 10−10), mental health conditions (depression OR 2.1 [1.6-2.8], p=1.1 × 10−6) and vitamin D deficiency (OR 1.8 [1.4-2.2], p=5.7 × 10−6). Renal diseases including end-stage renal disease and anemia due to chronic renal disease were the predominant premorbid risk factors for COVID-19 inpatient admission. Other less established risk factors for COVID-19 inpatient admission included previous renal transplant (OR 9.7 [2.8-39], p=3.2×10−4) and disorders of the immune system (OR 6.0 [2.3, 16], p=2.7×10−4). Prior use of oral steroid medications was associated with decreased COVID-19 positive testing risk (OR 0.61 [0.45, 0.81], p=4.3×10−4), but increased inpatient admission risk (OR 4.5 [2.3, 8.9], p=1.8×10−5). We did not observe that prior use of angiotensin converting enzyme inhibitors or angiotensin receptor blockers increased the risk of testing positive for SARS-CoV-2, being admitted to the hospital, or having a severe outcome. This study involving direct EHR extraction identified known and less well-established demographics, and prior diagnoses and medications as risk factors for COVID-19 susceptibility and inpatient admission. Knowledge of these risk factors including marked ethnic disparities observed in disease severity should guide government policies, identify at-risk populations, inform clinical decision making, and prioritize future COVID-19 research.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants R25NS065723 from the Neurological Disorders and Stroke of the National Institutes of Health and the UCLA David Geffen School of Medicine - Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research Award Program.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was considered human subjects research exempt because all electronic health records were de-identified (UCLA IRB# 20-001180).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe EHR dataset is not publicly available due to reasonable privacy and security concerns unless researchers are among the Institutional Review Board-approved research collaborations with the named medical centers. ER -